RecruitingNot ApplicableNCT07070765

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINT

Sponsor

University of Aberdeen

Enrollment

70 participants

Start Date

Dec 12, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Sodium-glucose transport-2 (SGLT-2) inhibitors and Standard medical treatment for people with breast cancer. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.